|
HS Code |
128862 |
| Chemical Formula | C13H11F2NO3 |
| Molecular Weight | 269.23 |
| Appearance | Typically a solid |
| Melting Point | Varies, specific data may need further research |
| Solubility | Solubility characteristics depend on solvents, e.g., may have limited solubility in water, better in organic solvents |
| Purity | Can be obtained in various purity levels depending on synthesis and purification methods |
| Odor | May be odorless or have a faint, characteristic odor |
| Stability | Stability under different conditions like light, heat, and air needs to be investigated |
As an accredited Methyl 5-(2,4-Difluorophenyl)-4-Methoxy-1H-Pyrrole-3-Carboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of Methyl 5-(2,4-Difluorophenyl)-4-Methoxy-1H-Pyrrole-3-Carboxylate in sealed chemical - grade bag. |
| Shipping | Methyl 5-(2,4 - Difluorophenyl)-4 - Methoxy - 1H - Pyrrole - 3 - Carboxylate is shipped in properly sealed containers, following strict chemical transportation regulations to ensure safety during transit. |
| Storage | Store “Methyl 5-(2,4-Difluorophenyl)-4-Methoxy-1H-Pyrrole-3-Carboxylate” in a cool, dry place away from direct sunlight. Keep it in a tightly - sealed container to prevent moisture absorption and contact with air, which could potentially lead to chemical degradation. Avoid storing near sources of heat or ignition due to its potential reactivity. |
In the cGMP orchestration of Type II ATP-competitive kinase inhibitor campaigns, the methyl ester at the 3-position remains latent until late-stage diversification—an intentional strategy to bypass premature decarboxylation during harsh cross-coupling steps. Production batches of the title pyrrole are charged as a 1.05 ± 0.02 molar equivalent component into a Vilsmeier-Haack formylation manifold, where POCl₃ is metered into anhydrous DMF at −5 °C in a 200 L glass-lined Pfaudler reactor. After the reagent complex forms, the substrate is introduced and the jacket temperature is ramped to 62 °C and held for 6 h; deviation beyond 65 °C triggers an exothermic run-away that oligomerizes the pyrrole nucleus, generating a toluene-insoluble tar quantified by thermogravimetric residue exceeding 4.2 wt% on a Mettler Toledo TGA/DSC 3+. The quench into chilled 2 M potassium acetate maintains a pH ≥ 8.0, preventing ester hydrolysis during phase separation. The resulting 2-formyl congener—obtained at 81–86 % isolated yield after trituration in n-heptane/ethyl acetate (4:1 v/v)—is telescoped into a reductive amination with a substituted aniline hinge-binder using STAB (sodium triacetoxyborohydride, 1.4 eq.) in dichloromethane containing 5 vol% acetic acid. Granulation and drying in a Comber double-cone vacuum dryer (≤ 50 °C, 10 mbar) delivers a milled powder with particle size D90 ≤ 45 µm, critical for uniform downstream slurry behaviour. The final API derived from this intermediate—a diarylamine-extended Type II VEGFR-2/PDGFRβ dual inhibitor—undergoes tablet compression on a KORSCH XL 400 rotary press with a target hardness of 8–12 kP; residual formyl intermediate content in the drug substance is controlled using a dedicated UPLC-MS method with a reporting threshold of 50 ppm, consistent with ICH M7 (R2) Stage 4 mutagenic impurity risk assessment. Water content of the isolated intermediate must stay below 0.3 % (Karl Fischer, ASTM E203) because moisture accelerates lactam formation with the adjacent methoxy group at 40 °C storage. Long-term stability chambers maintain 25 °C/60 % RH conditions per ICH Q1A(R2), with out-of-specification colour shift from off-white to amber being the earliest shelf-life failure indicator.What Are the Critical Purity Thresholds for Phenylpyrrole Fungicide Precursors?Deployment of the methyl ester as a building block for contact fungicides in the phenylpyrrole class demands conversion of the C-3 carboxylate into a cyano group, mimicking the pharmacophore of registered a.i.s such as fenpiclonil. The process route exploits a two-step sequence: alkaline hydrolysis in 1.5 eq. NaOH/MeOH-water (3:1 v/v) at 30 °C for 3 h to release the free acid (monitored by TLC, eluting at Rf = 0.18 in hexane:EtOAc 1:2), followed by in-situ amidation via CDI (1,1′-carbonyldiimidazole) activation and ammonia sparging at 0–5 °C. Dehydration of the primary amide with trifluoroacetic anhydride in the presence of triethylamine (1.05 eq.) in methyl tert-butyl ether at 10 °C affords 5-(2,4-difluorophenyl)-4-methoxy-1H-pyrrole-3-carbonitrile in 82–88 % crude yield. Vacuum distillation at 135 °C/0.8 mbar using a wiped-film evaporator (Pope Scientific) raises the GC purity to ≥ 98.5 %, but the critical quality attribute for registration under EU PPP Regulation (EC) No. 1107/2009 is the individual content of des-fluoro and cyano-hydrolysed dimers. These by-products, quantified by an in-house-validated HPLC-DAD method relative to the active, must not exceed 0.15 % area each, falling within the current CIPAC MT 46.3 reproducibility envelope of ± 3 % RSD. The technical-grade active substance is milled in an air-jet mill (Jet-O-Mizer 00) to a mean volume diameter of 2.5–4.0 µm (Malvern Mastersizer 3000, wet dispersion in 0.1 % Tween 80), enabling a 350 g/L flowable concentrate for seed treatment. Formulators must pre-disperse the melt-cast solid in a rotor-stator (Silverson L5M-A) at 5,000 rpm for 20 min before bead-milling with 0.4–0.6 mm yttria-stabilized zirconia beads to avoid blockages in the downstream 10 µm inline filter. Field efficacy against Fusarium graminearum is retained only when the 5-(2,4-difluorophenyl) ring remains intact; photolytic defluorination under simulated sunlight (Xenon arc, 765 W/m², ISO 11341:2004) generates a benign des-fluoro metabolite with a half-life of 4.2 h in aqueous pH 7 buffer, warranting controlled shading during manufacture. A comparative impurity limit table for the two largest-volume supply chains follows.
Non-Fullerene Acceptor Core Expansion via Pd-Catalysed Direct ArylationLow-bandgap copolymers with A–D–A architecture employ the methyl 5-(2,4-difluorophenyl)-4-methoxy-1H-pyrrole-3-carboxylate scaffold as an electron-deficient central core after the ester is transformed into a dicyanovinyl indanone end group. The synthetic entry requires selective hydrolysis of the methyl ester to the carboxylic acid (LiOH, THF/H₂O 4:1, 40 °C, 8 h, then acidification to pH 2 with dilute HCl) to enable a subsequent Steglich esterification with 2-(5,6-difluoro-3-oxo-3H-inden-1-ylidene)malononitrile. The crude acceptor is purified by flash chromatography (silica gel, gradient from 30 % to 70 % chloroform in hexane) and then further refined by train sublimation at 210 °C/10⁻⁶ mbar in a three-zone furnace (CREAPHYS) until the metal content drops below 10 ppb as measured by ICP-MS (Agilent 7900). Cyclic voltammetry in 0.1 M Bu₄NPF₆ acetonitrile solution (CHI660E potentiostat, scan rate 100 mV/s, ferrocene internal reference) reveals a LUMO of −3.92 eV and a HOMO of −5.68 eV, placing the acceptor appropriately for pairing with a PBDB-T donor. When incorporated into inverted bulk-heterojunction devices (ITO/ZnO/active layer/MoO₃/Ag), the blend was spin-coated from chlorobenzene with 3 vol% 1,8-diiodooctane at 2,000 rpm and annealed at 120 °C on a hot plate for 10 min; J–V characteristics measured under 100 mW/cm² AM 1.5 G illumination per ASTM E948-15 gave a PCE of 8.7 % with a short-circuit current of 17.2 mA/cm². Transient photovoltage decay (TPV) on a Paios all-in-one platform indicated that the charge carrier lifetime drops sharply when the acceptor loading exceeds 55 wt% due to over-purified domains, defining an optimal 1:1.2 donor:acceptor weight ratio. Mechanical robustness of the device stack relies on the pyrrole’s methoxy substituent suppressing excessive crystallisation; grazing-incidence wide-angle X-ray scattering (GIWAXS) at the q = 0.28 Å⁻¹ lamellar peak shows a coherence length reduction of 2.3 nm relative to the 4-unsubstituted analogue. Pilot-scale OPV module assembly on a roll-to-roll slot-die coater (FOM Technologies) uses the sublimed lot exclusively, as trace palladium up to 50 ppm from the direct arylation step quenches excitons and reduces fill factor to 44 %.When the 5-(2,4-Difluorophenyl) Motif Enters an Antiviral Prodrug StrategyOral bioavailability of carboxylate-based antiviral pharmacophores—specifically influenza cap-dependent endonuclease inhibitors or HIV-1 integrase strand transfer inhibitors (INSTIs)—is frequently rescued by the methyl esterification of the pyrrole-3-carboxylic acid hinge. The intact title methyl ester is directly formulated as a prodrug, avoiding an additional deprotection step in the API synthesis. Wet granulation of the active ester with microcrystalline cellulose (Avicel® PH-102) and croscarmellose sodium (3 wt%) in a Glatt GPCG 3.1 fluid-bed granulator at an inlet air temperature of 55 °C and a spray rate of 12 g/min binder solution (Povidone K30 in purified water) yields granules with a Hausner ratio of 1.09. Tablets compressed on a Riva Piccola rotary press to a breaking force of 90 N (Dr. Schleuniger 8M) are film-coated in a perforated pan (Colorcon Opadry® II Yellow, 3.5 % weight gain). In vitro dissolution in 900 mL of pH 1.2 HCl and pH 6.8 phosphate buffer according to USP <711> Apparatus 2 (paddle at 75 rpm) consistently releases ≥ 85 % of the labeled dose within 45 min, while the primary hydrolysis product, the free carboxylic acid, remains below 1.2 % in the acidic stage due to the electron-withdrawing 2,4-difluorophenyl group stabilizing the ester linkage. Forced degradation in 3 % H₂O₂ at 70 °C for 6 h confirms that the major degradant is the N-oxide generated at the pyrrole ring, underscoring the need for aluminium foil cold-form blister packaging (relative humidity < 10 %) to suppress oxidative discolouration during ICH Zone IVb stability studies. Toxicological batch release demands a nitrosamine risk assessment per EMA/CHMP/QWP/519478/2020; the methyl ester’s synthetic route avoids secondary amine solvents entirely, reducing N-nitroso-dimethylamine (NDMA) carry-over probability below the 0.03 ppm detection limit of an LC-APCI-MS/MS method with an LOQ of 0.01 ppm.Contract research organisations servicing fragment-based drug discovery (FBDD) procure the title compound as a shape-diverse fluorinated heterocycle with a balanced Log D₇.₄ of 2.8 (shake-flask, n-octanol/PBS). The milligram-to-gram supply, typically provided in a 96-well microplate format or as individual 4 mL amber vials under argon, arrives with a Certificate of Analysis enumerating 1 H-13C NMR (Bruker AVANCE NEO 500 MHz), HRMS (Q-TOF, ESI⁺), and combustion analysis (Elementar vario EL cube, C, H, N within ± 0.4 % of theoretical). Surface plasmon resonance (SPR) screening on a Biacore 8K system immobilising the target kinase through a His-tag captures a KD of 28 µM for the unoptimised fragment, a value that triggers a hit-to-lead expansion programme after soaking into the ATP-binding site of co-crystals grown under 12 % PEG 3350 at 4 °C (synchrotron diffraction at 1.75 Å). For cell-based assays, a 10 mM DMSO stock is diluted into assay buffer maintaining a final DMSO content ≤ 0.1 % to prevent solvent-induced cytotoxicity. Organisations operating under ISO 9001:2015 store the compound at −20 °C in a dedicated inert-atmosphere glovebox (MBraun, O₂/H₂O ≤ 0.5 ppm), with inventory tracking compliant to 21 CFR Part 11 electronic records. However, prolonged storage beyond 12 months is discouraged because the ester’s gradual hydrolysis in frozen DMSO aliquots—accelerated by repetitive freeze-thaw cycles exceeding 6 iterations—produces an acidic shift that precipitates the free acid, introducing a 3 % false-negative hit rate in protein-based biophysical screens. |
Competitive Methyl 5-(2,4-Difluorophenyl)-4-Methoxy-1H-Pyrrole-3-Carboxylate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Analogue | MW (g/mol) | clogP | cLogD₇.₄ | pKₐ (NH) | tPSA (Ų) | HOMO (eV)¹ |
|---|---|---|---|---|---|---|
| 4‑OCH₃ (target) | 265.22 | 2.81 | 2.74 | 13.2 | 57.4 | −5.92 |
| 4‑OC₂H₅ | 279.25 | 3.29 | 3.22 | 13.3 | 57.4 | −5.81 |
| 4‑CH₃ | 249.22 | 3.15 | 3.14 | 13.6 | 37.3 | −5.68 |
| 4‑H | 235.19 | 2.44 | 2.42 | 13.7 | 37.3 | −5.45 |